| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
3-Acetyl-beta-boswellic acid targets 5-lipoxygenase (5-LO), functioning as a non-reducing inhibitor. It also targets DNA, RNA, and protein synthesis pathways in cancer cells. The compound increases apoptosis and the activity of caspase 3/7. It inhibits cell proliferation, decreases DNA synthesis, and inhibits the migration, invasion, and colony formation of human glioblastoma cell lines. Its anti-inflammatory effects are mediated through 5-LO inhibition.
|
|---|---|
| ln Vitro |
In vitro, 3-Acetyl-beta-boswellic acid inhibits synthesis of DNA, RNA, and protein in human leukemia HL-60 cells with IC50 values ranging from 0.6 to 7.1 μM. It inhibits cell proliferation, decreases DNA synthesis, and inhibits the migration, invasion, and colony formation of human glioblastoma cell lines. The compound increases apoptosis and caspase 3/7 activity. It is a non-reducing inhibitor of 5-lipoxygenase (5-LO). Its anti-tumor and anti-inflammatory activities have been characterized in various cell-based assays.
|
| ln Vivo |
In vivo, 3-Acetyl-beta-boswellic acid has antitumor activity. It exhibits anti-inflammatory, anti-tumor, and antioxidant effects. The compound's inhibition of 5-lipoxygenase suggests potential for treating inflammatory diseases. Its anti-tumor effects have been demonstrated in preclinical models. Further in vivo studies are ongoing to fully characterize its therapeutic potential. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
In vitro enzyme assays for 3-Acetyl-beta-boswellic acid involve measuring 5-lipoxygenase (5-LO) inhibition. 5-LO activity is assessed by monitoring the conversion of arachidonic acid to leukotrienes. The compound is added at varying concentrations, and IC50 values are calculated from dose-response curves. For DNA, RNA, and protein synthesis inhibition, HL-60 cells are treated with the compound and incorporation of radiolabeled precursors is measured. Apoptosis is assessed by measuring caspase 3/7 activity. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for 3-Acetyl-beta-boswellic acid are conducted in HL-60 leukemia cells, glioblastoma cell lines, and other cancer cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. DNA, RNA, and protein synthesis are assessed by measuring incorporation of radiolabeled precursors. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Migration and invasion are assessed using Transwell assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
3-Acetyl-beta-boswellic acid in vivo studies are conducted in animal models of cancer and inflammation. Tumor-bearing mice are treated with the compound via oral administration or injection. Tumor growth is monitored by caliper measurements. Apoptosis in tumors is assessed by TUNEL assay and caspase activity measurement. For anti-inflammatory studies, animal models of inflammation such as carrageenan-induced paw edema are used. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
3-Acetyl-beta-boswellic acid (MW 498.74 g/mol, C32H50O4) is a triterpenoid compound. It is a non-reducing inhibitor of 5-lipoxygenase (5-LO). The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. 3-Acetyl-beta-boswellic acid is a natural product from Boswellia with anti-inflammatory and anti-tumor activities. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
3-Acetyl-beta-boswellic acid is generally well-tolerated in preclinical studies. The compound is a natural triterpenoid with established safety profiles. Its anti-inflammatory, anti-tumor, and antioxidant effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
It has been reported that frankincense (Boswellia sacra) and saw-tooth frankincense (Boswellia serrata) contain 3-acetyl-β-boswellic acid, and relevant data are available for reference.
3-Acetyl-beta-boswellic acid (3-O-Acetyl-beta-boswellic acid) is a non-reducing inhibitor of 5-lipoxygenase (5-LO) with antitumor effects. It inhibits DNA, RNA, and protein synthesis in HL-60 cells with IC50 values of 0.6-7.1 μM. The compound inhibits glioblastoma cell proliferation, migration, invasion, and colony formation, and increases apoptosis and caspase 3/7 activity. It exhibits anti-inflammatory, anti-tumor, and antioxidant effects. All applications are limited to non-human research use. |
| Molecular Formula |
C32H50O4
|
|---|---|
| Molecular Weight |
498.7370
|
| Exact Mass |
498.37
|
| CAS # |
5968-70-7
|
| PubChem CID |
11386458
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
566.8±50.0 °C at 760 mmHg
|
| Melting Point |
157-161ºC
|
| Flash Point |
171.4±23.6 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.544
|
| LogP |
10.27
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
36
|
| Complexity |
985
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H]([C@]5(C)C(=O)O)OC(=O)C)C)C)[C@@H]2[C@H]1C)C)C
|
| InChi Key |
YJBVHJIKNLBFDX-MQURJEHKSA-N
|
| InChi Code |
InChI=1S/C32H50O4/c1-19-11-14-28(4)17-18-30(6)22(26(28)20(19)2)9-10-23-29(5)15-13-25(36-21(3)33)32(8,27(34)35)24(29)12-16-31(23,30)7/h9,19-20,23-26H,10-18H2,1-8H3,(H,34,35)/t19-,20+,23-,24-,25-,26+,28-,29-,30-,31-,32-/m1/s1
|
| Chemical Name |
(3R,4R,4aR,6aR,6bS,8aR,11R,12S,12aR,14aR,14bR)-3-acetyloxy-4,6a,6b,8a,11,12,14b-heptamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picene-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0051 mL | 10.0253 mL | 20.0505 mL | |
| 5 mM | 0.4010 mL | 2.0051 mL | 4.0101 mL | |
| 10 mM | 0.2005 mL | 1.0025 mL | 2.0051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
